A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...
GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
The assay is designed to encourage informed patient-physician decision-making when choosing a treatment option in localised ...
Scientists at NYU Langone Health examined cancerous and benign tissues from 10 patients with prostate cancer and found “small ...
An independent group of medical experts with the U.S. Preventative Services Task Force recommends that men of all ages no longer be screened using the prostate-specific antigen blood test to check for ...
Scientists comment on the Prostate Cancer Research report that reviews the economic model used to inform decisions on prostate cancer screening in the UK. Prof Hashim Ahmed, Professor of Urology, ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results